Najat Khan
CEO, President & Director

Good morning, everyone, and thank you for joining us. Since stepping into this role, I've been focused on a singular question: how do we harness the full power of AI to consistently and with urgency create better medicines for patients? That requires bold ambition and a lot of focus and discipline to create value for patients and shareholders. And therefore, our approach has been deliberate.

First, we're focusing on signal over noise, generating proof and proof points across our both wholly owned programs and our partner programs with the goal to showcase where AI can truly make a difference in creating value. Second, we are continuing to evolve our platform into a repeatable, AI-driven product engine, not tech for the sake of tech, but tech that creates products of value. And third, underpinning it all is a strong commitment to financial discipline and thoughtful capital allocation, ensuring we're constantly being data-driven to prioritize and invest in our highest conviction opportunities to deliver durable value.

Today, I'm excited to share some of our updates. We're making meaningful progress across all these fronts, which I, along with Vicki and Ben, will share more with you today. With that, let's dive in. But before we do, please note that today we'll be making forward-looking statements on this call, and therefore, please refer to our SEC filings for more information.

To put the progress in context, I think it's worth briefly stepping back to how we built the foundation to enable it. Look, Recursion has been on an intentional and, in many ways, a pioneering journey. Early